OncoBEAM testing for breast cancer

blications Breast Cancer

Rugo H, Mayer E, Storniolo A, et al. (2019) Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers. Cancer Res. 79(4 Supplement):PD2-12.  Link: Abstract
 
Di Leo A, Johnston S, Lee KS, et al. (2018) Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2018;19(1):87-100 Link: Pubmed
 
Juric D, Krop I, Ramanathan RK, et al. (2017) Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. 7(7):704-715.  Links: Pubmed Free PDF
 
de Bruin EC, Whiteley JL, Corcoran C, et al. (2017) Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients. Wang H, ed. PLOS ONE. 12(5):e0175779.  Links: Pubmed Free PDF
 
Spoerke JM, Gendreau S, Walter K, et al. (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications. 7(1):11579. Links: Pubmed Free PDF
Rudolph M, Anzeneder T, Schulz A, et al. (2016) AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer. 16(1):622. Links: Pubmed Free PDF
 
Baselga J, Im S-A, Iwata H, et al. (2015) PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial. SABCS2015/S6-01 Link: Abstract
 

Higgins M, Jelovac D, Barnathan E, et al. (2012) Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012 Jun 15;18(12):3462-9 Links: Pubmed Free PDF